Next Article in Journal
egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions
Previous Article in Journal
Progression-Free Survival as a Clinical Trial Endpoint in Advanced Renal Cell Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 18
Issue s2
10.3747/co.v18is2.941
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer

by
S. Gill
1,*,
S. Berry
2,
J. Biagi
3,
C. Butts
4,
M. Buyse
5,
E. Chen
6,
D. Jonker
7,
C. Mărginean
8,
B. Samson
9,
J. Stewart
10,
M. Thirlwell
11,
R. Wong
12 and
J.A. Maroun
13
1
University of British Columbia, Division of Medical Oncology, and BC Cancer Agency, Vancouver, BC, Canada
2
Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, ON, Canada
3
Department of Oncology, Queen’s University, Kingston, ON, Canada
4
Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada
5
International Drug Development Institute, Louvain-la-Neuve, and I-BioStat, Hasselt University, Diepenbeek, Belgium
6
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
7
Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
8
Ottawa Hospital Research Institute, Ottawa, ON, Canada
9
Centre intégré de Cancer de la Montérégie de l’Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada
10
University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
11
McGill University, McGill University Health Centre, and Montreal General Hospital, Montreal, QC, Canada
12
CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada
13
Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(s2), 5-10; https://doi.org/10.3747/co.v18is2.941
Submission received: 6 September 2011 / Revised: 8 September 2011 / Accepted: 12 September 2011 / Published: 1 October 2011

Abstract

In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement in overall survival has been considered the “gold standard”—the most convincing measure of efficacy. However, overall survival requires larger patient numbers and longer follow-up and may often be confounded by other factors, including subsequent therapies and crossover. Given the number of active therapies for potential investigation, demand for rapid evaluation and early availability of new therapies is growing. Progression-free survival is regarded as an important measure of treatment benefit and, compared with overall survival, can be evaluated earlier, with fewer patients and no confounding by subsequent lines of therapy. The present paper reviews the advantages, limitations, and relevance of progression-free survival as a primary endpoint in randomized trials of metastatic colorectal cancer.
Keywords: progression-free survival; metastatic colorectal cancer; surrogate endpoints; targeted therapies; randomized clinical trials progression-free survival; metastatic colorectal cancer; surrogate endpoints; targeted therapies; randomized clinical trials

Share and Cite

MDPI and ACS Style

Gill, S.; Berry, S.; Biagi, J.; Butts, C.; Buyse, M.; Chen, E.; Jonker, D.; Mărginean, C.; Samson, B.; Stewart, J.; et al. Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. Curr. Oncol. 2011, 18, 5-10. https://doi.org/10.3747/co.v18is2.941

AMA Style

Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, Jonker D, Mărginean C, Samson B, Stewart J, et al. Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. Current Oncology. 2011; 18(s2):5-10. https://doi.org/10.3747/co.v18is2.941

Chicago/Turabian Style

Gill, S., S. Berry, J. Biagi, C. Butts, M. Buyse, E. Chen, D. Jonker, C. Mărginean, B. Samson, J. Stewart, and et al. 2011. "Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer" Current Oncology 18, no. s2: 5-10. https://doi.org/10.3747/co.v18is2.941

APA Style

Gill, S., Berry, S., Biagi, J., Butts, C., Buyse, M., Chen, E., Jonker, D., Mărginean, C., Samson, B., Stewart, J., Thirlwell, M., Wong, R., & Maroun, J. A. (2011). Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. Current Oncology, 18(s2), 5-10. https://doi.org/10.3747/co.v18is2.941

Article Metrics

Back to TopTop